

Limited Review Report

**The Board of Directors
TAKE Solutions Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results (the statement) of TAKE Solutions Limited for the quarter ended June 30, 2021. This statement which is the responsibility of the Company's Management has been approved by the Board of Directors. The statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. We draw attention to the following matter in the Notes to the standalone financial results:
 - a. The management has taken into consideration the impact of the known internal and external events arising from COVID-19 pandemic in the assessment of recoverability of trade receivables, contract assets and certain investments in subsidiaries up to the date of approval of these financial results. In this assessment, the company has performed sensitivity analysis on the key assumptions used. Such review and analysis performed by the company did not reveal any impairment losses.

Since the impact assessment of COVID-19 is an ongoing process given the uncertainties associated with its nature and duration, the Company will continue to closely monitor any significant impact on the financial position. The impact of global health pandemic might be different from that estimated as at the date of approval of these financial results.
 - b. As at March 31, 2021, the income from financial assets and financial assets exceeded 50% of gross income and total assets respectively due to which the company satisfied the



"principal business criteria" for Non-Banking Financial Company (NBFC) as per RBI directives. The company, on the basis of its operational plans believes that this scenario would be temporary and the quarterly financial results for the quarter ended June 30, 2021 have been prepared in the formats applicable to the companies other than NBFCs.

Our conclusion is not modified in respect of the above matters.

For G. D. Apte & Co.
Chartered Accountants
Firm Registration Number: 100515W
UDIN: 21113053AAAACR8455



Umesh S. Abhyankar
Partner
Membership Number: 113 053
Pune, August 11, 2021





TAKE SOLUTIONS LTD

CIN: L63090TN2000PLC046338

Regd. Office : 27, Tank Bund Road, Nungambakkam, Chennai 600 034

www.takesolutions.com

Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2021

(₹ in Lakhs except per share data)

Sl. No.	Particulars	Quarter Ended			
		Jun 30, 2021	Mar 31, 2021	Jun 30, 2020	Mar 31, 2021
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
A	CONTINUING OPERATIONS				
1	Revenue from operations	-	-	1.73	186.09
2	Other Income	692.41	69.25	433.53	1,035.63
3	Total Income	692.41	69.25	435.26	1,221.72
4	Expenses				
	Cost of revenue	-	-	1.59	154.94
	Employee benefit expenses	98.63	103.87	122.93	412.35
	Finance cost	7.86	8.28	9.49	35.57
	Depreciation and amortisation	35.76	39.06	39.24	156.78
	Other expenses	234.29	141.30	192.40	1,192.15
	Total Expenses	376.54	292.51	365.65	1,951.79
5	Profit/(Loss) before exceptional items and tax (3-4)	315.87	(223.26)	69.61	(730.07)
6	Exceptional items				
	Profit on sale of subsidiary	-	-	-	1,381.81
7	Profit/(Loss) before tax (5+6)	315.87	(223.26)	69.61	651.74
8	Tax expense				
	Current tax	14.15	-	12.34	-
	Shortfall / (excess) provision of earlier years	-	(99.70)	-	(99.70)
	Deferred tax	(39.07)	0.54	(41.96)	(27.82)
9	Profit/(Loss) for the period from continuing operations (7-8)	340.79	(124.10)	99.23	779.26
B	DISCONTINUED OPERATIONS				
10	Profit/(Loss) from discontinued operations before tax	-	-	-	-
11	Less: Tax expense on discontinued operations	-	-	-	-
12	Profit/(Loss) for the period from discontinued operations (10-11) after tax	-	-	-	-
13	Profit/(Loss) for the period (9+12)	340.79	(124.10)	99.23	779.26
14	Other Comprehensive Income				
a)	i) Items that will not be reclassified to profit or (loss)	1.52	(7.29)	(0.92)	5.73
	ii) Income tax provision / (reversal) relating to the items that will not be reclassified to profit or (loss)	0.38	(1.84)	(0.23)	1.44
b)	i) Items that will be reclassified to profit or (loss)	-	-	-	-
	ii) Income tax provision/(reversal) relating to the items that will be reclassified to profit or (loss)	-	-	-	-
	Total Other Comprehensive Income	1.14	(5.45)	(0.69)	4.29
15	Total Comprehensive Income	341.93	(129.55)	98.54	783.55
16	Paid-up equity share capital (Face value ₹ 1/- each)	1,479.34	1,479.34	1,479.34	1,479.34
17	Earnings per share (of ₹ 1/- each) (not annualised)				
	(a) Basic (in ₹)	0.23	(0.08)	0.07	0.53
	(b) Diluted (in ₹)	0.23	(0.08)	0.07	0.53

Note:

- The Standalone Financial Results for the quarter ended June 30, 2021 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the company in their respective meetings held on August 11, 2021. The statutory auditors of the company have carried out Limited Review of the results for the quarter ended June 30, 2021.
- The management has taken into consideration the impact of the known internal and external events arising from COVID-19 pandemic in the assessment of recoverability of trade receivables, contract assets and certain investments in subsidiaries up to the date of approval of these Standalone Financial results. In this assessment, the company has performed sensitivity analysis on the key assumptions used. Such review and analysis performed by the company did not reveal any impairment losses. Since the impact assessment of COVID-19 is an ongoing process given the uncertainties associated with its nature and duration, the Company will continue to closely monitor any significant impact on the financial position. The impact of global health pandemic might be different from that estimated as at the date of approval of these financial results.
- The Company on 06 August 2021 has entered into a definitive agreement for a strategic partnership with an affiliate of H I Q Capital to effect the sale of 75% of equity interest in the company's clinical research organisation business conducted by the company's subsidiaries in India and overseas. The completion of the proposed transaction is subject to approval of the shareholders of the Company, receipt of lender, governmental and contractual consents.
- As at March 31, 2021, the income from financial assets and financial assets exceeded 50% of gross income and total assets respectively due to which the company satisfied the 'principal business criteria' for Non-Banking Financial Company (NBFC) as per RBI directives. The company, on the basis of its operational plans believes that this scenario would be temporary and the quarterly financial results for the quarter ended June 2021 have been prepared in the formats applicable to the companies other than NBFCs.
- The Code on Social Security, 2020 (the Code) has been enacted, which would impact contribution by the Company towards applicable social security schemes. The Ministry of Labour and Employment has also released draft rules thereunder on November 13, 2020 and has invited suggestions from stakeholders which are under active consideration by the Ministry. The actual impact on account of this change will be evaluated and accounted for when notification becomes effective.
- The company on a standalone basis operates in the business segment of promotion of services related to Life Sciences and hence there is only one business segment. The company on a standalone basis is primarily operating in India, which is considered as single geographical segment. Accordingly, segment information has not been separately disclosed.
- During the quarter ended June 30, 2021, employees have not exercised any equity share options under Employee Stock Option Scheme of the Company.
- Previous period figures have been regrouped /reclassified, wherever necessary to conform to current period's classification.

For and on behalf of the Board of Directors



Brinvaan H.R.

Brinvaan H.R.

Vice Chairman & Managing Director

Place : Chennai

Date : August 11, 2021

